Table 1.

Lipid-lowering treatments and LDL cholesterol targets in Heterozygous familial hypercholesterolemia

Study	Study size	Treatment	Control
[12]a	N = 1852 (1262 FH and 590 relatives non FH)	LLT: 83.7% (97% FH and 78% relatives FH) Statins monotherapy: 58.3% Statin + ezetimibe: 31.3%	LDLc <100 mg/dl: 33 (3.4%) of FH on LLT
[13]b	N = 527 (241 HeFH and 286 combined FH)	LLT: 100% 1 year after study entry Statins: 94.3% Ezetimibe: 33.4%	LDLc <100 mg/dl: 28.5%
[14]	37 HeFH and 37 controls	Statins: 100% HeFH and 100% no-HeFH Ezetimibe: 23 (62.2%) HeFH; 4 (10.8%) no-HeFH	LDLc <100 mg/dl: 11% of HeFH

LLT lipid-lowering treatment, FH familiar hypercholesterolemia, LDLc low-density lipoprotein cholesterol, HeFH heterozygous familial hypercholesterolemia

^aOnly 13% received maximum daily statin doses, defined as simvastatin 80 mg, pravastatin 40 mg, lovastatin 80 mg, fluvastatin 80 mg, atorvastatin 80 mg, rosuvastatin 20–40 mg or maximum statin dose plus ezetimibe 10 mg/day

^bThe strength of the lipid-lowering treatment in HeFH patients was considered low (lovastatin 10–40 mg, fluvastatin 80 mg, pravastatin 20–40 mg, simvastatin 10–20 mg, atorvastatin 10 mg) in 6.9% of cases, moderate (lovastatin 80 mg, simvastatin 40 mg, atorvastatin 20–40 mg, rosuvastatin 5–10 mg, simvastatin + ezetimibe 20 + 10 mg) in 40% and high (atorvastatin 80 mg, rosuvastatin 20 mg, simvastatin + ezetimibe 40 + 10 mg) in 53%